Immuneering Corporation

NASDAQ:IMRX

1.45 (USD) • At close April 25, 2025
Overview | Financials

Numbers are in millions (except for per share data and ratios) USD.

2024 Q42024 Q32024 Q22024 Q12023 Q42023 Q32023 Q22023 Q12022 Q42022 Q32022 Q22022 Q12021 Q42021 Q32021 Q22021 Q12020 Q42020 Q32020 Q22020 Q1
Revenue 0000-94.419094.419000.0380.0940.1840.190.4820.660.7480.6650.6830.4810.483
Cost of Revenue 000.1750.1880.1850.1960.1940.19157.9640.0190.0480.0910.2060.2190.3190.4090.4730.3150.2370.255
Gross Profit 00-0.175-0.188-94.604-0.19694.225-0.19-157.9630.0190.0460.093-0.0170.2630.3410.3390.1920.3680.2440.228
Gross Profit Ratio 0000000.9980-346,411.0130.4960.4920.505-0.0880.5460.5170.4530.2880.5390.5070.472
Reseach & Development Expenses 14.85711.25310.65211.14111.9110.059.45310.2119.8729.3647.9819.0597.956.2076.9925.3914.894.0693.2212.823
General & Administrative Expenses 3.6944.0144.2544.1164.3853.8694.0454.4614.1063.8363.7043.9523.1492.5991.341.1841.1380.6990.6290.644
Selling & Marketing Expenses 000-0.1190000000000000000
SG&A 3.6944.0144.2543.9974.3853.8694.0454.4614.1063.8363.7043.9523.1492.5991.341.1841.1380.6990.6290.644
Other Expenses 0.0070.007-0.1680.2130.4640.0070.150.0070.0070.007-0.0240.008-0.119-0.008000000
Operating Expenses 18.55815.27414.73815.13816.30313.92613.50514.67913.98513.20711.69213.01911.0998.8068.3326.5756.0284.7683.853.467
Operating Income -18.558-15.274-14.914-15.326-16.302-13.926-13.505-14.68-13.985-13.188-11.646-12.926-11.116-8.543-7.991-6.236-5.836-4.4-3.607-3.239
Operating Income Ratio 000000-0.1430-30,668.875-343.62-123.344-70.364-58.63-17.72-12.107-8.335-8.776-6.447-7.501-6.706
Total Other Income Expenses Net 0.5060.6760.8341.0181.2181.3311.3161.0750.7390.3440.1190.0290.0240.0090.0030.00600.0010.0030.038
Income Before Tax -18.052-14.597-14.08-14.308-15.084-12.595-12.189-13.604-13.246-12.844-11.527-12.897-11.092-8.534-7.987-6.23-5.836-4.399-3.604-3.201
Income Before Tax Ratio 000000-0.1290-29,047.285-334.661-122.085-70.205-58.504-17.701-12.101-8.326-8.775-6.445-7.495-6.626
Income Tax Expense 00-0-0-0.755-13,912.372-1.139-1,075.403-0.74-0.344-0.052-0.029-0.307-0.0170.00100.042-00.0010
Net Income -18.051-14.597-14.08-14.308-15.083-12.595-12.1891,061.799-12.506-12.501-11.527-12.867-10.784-8.534-7.988-6.23-5.836-4.399-3.604-3.201
Net Income Ratio 000000-0.1290-27,424.346-325.704-122.087-70.045-56.882-17.701-12.102-8.326-8.775-6.445-7.496-6.626
EPS -0.6-0.49-0.47-0.49-0.52-0.43-0.4340.16-0.47-0.47-0.44-0.49-0.42-0.47-0.33-0.46-0.43-0.33-0.27-0.24
EPS Diluted -0.6-0.49-0.47-0.49-0.52-0.43-0.4340.16-0.47-0.47-0.44-0.49-0.42-0.47-0.33-0.46-0.43-0.33-0.27-0.24
EBITDA -18.465-15.177-14.816-15.228-14.898-13.841-13.419-14.596-13.901-13.113-11.584-12.696-11.039-8.497-7.953-6.196-5.762-4.383-3.588-3.224
EBITDA Ratio 000000-0.1420-30,484.274-341.656-122.689-69.112-58.227-17.623-12.049-8.281-8.663-6.422-7.462-6.674